Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 668Neoplasms 585Colorectal Neoplasms 289Carcinoma, Non-Small-Cell Lung 287Prostatic Neoplasms 277Lung Neoplasms 219Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 147Head and Neck Neoplasms 142Pancreatic Neoplasms 140Ovarian Neoplasms 129Carcinoma, Hepatocellular 127Leukemia, Myeloid, Acute 120Brain Neoplasms 114Squamous Cell Carcinoma of Head and Neck 110Colonic Neoplasms 109Uterine Cervical Neoplasms 107Recurrence 103Stomach Neoplasms 102Lymphoma 100Glioblastoma 91Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Urinary Bladder Neoplasms 77Lymphoma, Follicular 77Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 73Sarcoma 71

Interventions

tislelizumab 1Oxaliplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mid-low Rectal Cancer × 1 year × Clear all
NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Completed
38 enrolled
Gastrointestinal

Mid-low Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡